We’re excited to welcome March (and the prospect of spring) with discussion of SARS-CoV-2 viral variants…what does this mean for testing? We’ll hear directly from FDA’s CDRH and from the team at LabCorp for updates on the emerging data and its implications. We’ll also report out from our early January retro and get a special update from FDA’s Chief Data Office. Join us!